EIHA Consortium Submits Novel Foods Application to FSA

EIHA projects GmbH, together with ChemSafe, their scientific provider, announced that they have submitted Novel Foods applications for natural CBD isolate and Full Spectrum; fully meeting the Food Safety Authority (FSA) deadline.

In addition to the toxicological studies package already designed and planned by the Consortium; focused on evaluating the safety of its novel food products, EIHA projects GmbH also decided to reinforce the applications by offering more comprehensive data on six years of stability tests to support the analytical profile and the stability of their products on the market.

New members joining daily

The EIHA Novel Food Consortium is currently supported by 183 partners with more newcomers joining daily. Now that the application has been submitted to the FSA, the next step is to undertake the submission to EFSA, to secure the products on the EU market.

“These past few months have been hectic and challenging, but I can assure you that every single minute spent on this project was definitely worth it. Since we came back from Christmas, we have welcomed 50 new Consortium partners, many of them SMEs. The facts speak for themselves: hemp operators want to be compliant with the market rules and are willing to do their part and take the necessary steps to meet the requirements. A united, professional, and safe market of hemp-derived products is what this sector needs, and we are on the right road”, said Ms. Lorenza Romanese, EIHA Managing Director.

“It goes without saying that I am extremely proud of the work that has been carried out by the Novel Food Taskforce and the sustained effort and trust of our members. We don’t make binding promises. We are here to do our best, and doing our best means providing the most comprehensive data and science-based evidence to support our joint application. Moreover, we are in direct contact with the authorities to ensure active and effective cooperation”, she added.

As a regular member of EIHA, Ilesol Pharmaceuticals is a member of the Novel Food Consortium from its foundation. Following the positive outcome of the Novel Food applications both to the FSA and the European Food Safety Authority (EFSA), our company’s products should be allowed to be marketed in the EU and UK with exclusivity on the Consortium’s study that will last five years.

The Consortium has agreed to invest up to €3,5 million for financing all relevant and unprecedented toxicological studies on CBD and THC. Last week, the EIHA announced the largest-ever study on the impacts of trace levels of THC on human health.

Reviewed by Sasha Bajilo, founder of ILESOL Pharmaceuticals, an industrial scale producer of CBD products and formulations. Expert on Hemp/Cannabis policy, member of the Croatian Ministry of Health regulatory commission for medical cannabis.